Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis

Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events

(2010) R. Rubinshtein et al.   EUROPEAN HEART JOURNAL

Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study

(2009) C. S. Brueckner et al.   ANNALS OF THE RHEUMATIC DISEASES

Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud's Phenomenon Secondary to Systemic Sclerosis

(2009) E. SCHIOPU et al.   JOURNAL OF RHEUMATOLOGY

Gastrointestinal symptoms and motility disorders in patients with systemic scleroderma

(2008) Agostino Di Ciaula et al.   BMC GASTROENTEROLOGY

Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication

(2008) Alfonso J De LaVega et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension

(2007) F Iannone et al.   ANNALS OF THE RHEUMATIC DISEASES